Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3963 |
| Name | thyroid gland carcinoma |
| Definition | A thyroid gland cancer that has_material_basis_in epithelial cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| RET C634W | Sorafenib | thyroid gland carcinoma | sensitive | detail... |
| RET C634W | Ponatinib | thyroid gland carcinoma | sensitive | detail... |
| RET M918T | Ponatinib | thyroid gland carcinoma | sensitive | detail... |
| RET C634W | Cabozantinib | thyroid gland carcinoma | sensitive | detail... |
| BRAF V600E PIK3CA H1047R | Dabrafenib + Everolimus + Trametinib | thyroid gland carcinoma | predicted - sensitive | detail... |
| BRAF V600E PIK3CA H1047R | Everolimus | thyroid gland carcinoma | resistant | detail... |
| BRAF V600E PIK3CA H1047R | Dabrafenib + Trametinib | thyroid gland carcinoma | resistant | detail... |
| BRAF V600E | Dabrafenib | thyroid gland carcinoma | predicted - sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | thyroid gland carcinoma | predicted - sensitive | detail... |
| RET M918T | Selpercatinib | thyroid gland carcinoma | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01208051 | Phase Ib/II | Cediranib + Lenalidomide Cediranib | Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer | Completed | USA | CAN | 0 |
| NCT01655719 | Phase II | Pioglitazone | Pioglitazone in Thyroid Cancers | Completed | USA | 0 |
| NCT02428712 | Phase Ib/II | PLX8394 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Completed | USA | 0 |
| NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Active, not recruiting | 0 | |
| NCT02834013 | Phase II | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
| NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04171622 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04619316 | Phase II | Dabrafenib + Trametinib Trametinib | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI) | Unknown status | DEU | 0 |
| NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Active, not recruiting | USA | 0 |
| NCT04940052 | Phase III | Dabrafenib + Trametinib | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer | Active, not recruiting | USA | TUR | CAN | BRA | ARG | 6 |
| NCT05852223 | Phase II | Pembrolizumab | Pembrolizumab in High-risk Thyroid Cancer (NePenThe) | Recruiting | ITA | 0 |
| NCT05949424 | FDA approved | Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) | Unknown status | NLD | 0 |
| NCT06959511 | Phase II | XL092 | Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | Recruiting | USA | 0 |